Caladrius Biosciences to Host 2019 Second Quarter Financial Results Conference Call on Thursday, August 8, 2019 at 4:30 p.m. ...
August 01 2019 - 8:30AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a late-stage therapeutics development biopharmaceutical
company pioneering advancements of cell therapies in select
cardiovascular and autoimmune diseases, announces that the
Company will release financial results for the six months ended
June 30, 2019 after close of the U.S. financial markets on
Thursday, August 8, 2019.
Caladrius’ management will host a conference
call for the investment community beginning at 4:30 p.m. ET on
Thursday, August 8, 2019 to discuss the financial results, provide
a company update and answer questions.
Shareholders and other interested parties may
participate on the conference call by dialing (866) 595-8403
(domestic) or (706) 758-9979 (international), using the conference
ID number: 4491545. The conference call will also be webcast live
and can be accessed from the Company’s website at
www.caladrius.com/investors/news-events.
For those unable to participate in the live
conference call or webcast, an audio recording will be available
for replay approximately two hours after the conclusion of the call
until 11:59 p.m. ET on August 15, 2019. To access the audio replay,
dial (855) 859-2056 (domestic) or (404) 537-3406 (international)
and provide conference ID number: 4491545.
A webcast replay of the conference call will
remain available on the Company’s website for 90 days.
About Caladrius
BiosciencesCaladrius is a late-stage therapeutics
development biopharmaceutical company pioneering advancements of
cell therapies for select cardiovascular and autoimmune
diseases. Our leadership team collectively has decades of
biopharmaceutical development experience and world-recognized
scientific achievement in the fields of cardiovascular and
autoimmune disease, among other areas. Our current product
candidates include three developmental treatments for
cardiovascular diseases based on our CD34+ cell therapy platform:
CLBS12, recipient of a SAKIGAKE designation, in a
registration-eligible trial in Japan and eligible for early
conditional approval for the treatment of critical limb ischemia;
CLBS16 (formerly known as CLBS14-CMD), subject of the
proof-of-concept ESCaPE-CMD clinical trial in the U.S.A. for the
treatment of coronary microvascular dysfunction; and CLBS14
(formerly known as CLBS14-NORDA), recipient of a RMAT designation
in the U.S.A. and for which we are in preparation to commence a
Phase 3 clinical trial in no option refractory disabling angina.
For more information on the company, please
visit www.caladrius.com.
Contact:
Investors: Caladrius Biosciences, Inc. John
Menditto Vice President, Investor Relations and Corporate
Communications Phone: +1-908-842-0084
Email: jmenditto@caladrius.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2024 to May 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From May 2023 to May 2024